The Role of PPARa in Cardiac Dysfunction in Sepsis
PPARa 在脓毒症心脏功能障碍中的作用
基本信息
- 批准号:10226912
- 负责人:
- 金额:$ 16.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-10 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAgonistBasic ScienceBone MarrowCardiacCardiovascular systemCell CompartmentationCessation of lifeChildChildhoodClinicalCritical CareDataData SetDown-RegulationEvaluationExperimental ModelsExpression ProfilingFDA approvedFailureFellowshipFunctional disorderGene ExpressionGenesGenetic TranscriptionHeartHeart InjuriesHistologicHormonesImmuneImmune responseImmunologyImpairmentInflammationInflammatoryInvestigationKnockout MiceKnowledgeLeadLeukocytesLifeLigandsMeasuresMedicineMentorsMetabolicMetabolic PathwayMetabolismMitochondriaMorbidity - disease rateMouse StrainsMultiple Organ FailureMusMyocardialMyocardial dysfunctionNuclearNuclear Hormone ReceptorsNuclear ReceptorsOrganOrgan failurePPAR alphaPathogenesisPathway AnalysisPatient-Focused OutcomesPharmacologyPhenotypePlasmaPlayProcess MeasureProductionPublic HealthRegulationResearchResearch PersonnelResearch Project GrantsResearch TrainingRoleSavingsSepsisSeptic ShockSeverity of illnessSignal PathwaySignal TransductionStatistical MethodsStructureSyndromeTestingTherapeutic InterventionTissuesTrainingTraining ProgramsTransgenic OrganismsTranslational ResearchTransplantationTroponinWild Type MouseWorkcecal ligation punctureclinically relevantexperimental studyfatty acid oxidationgain of functiongenome-wideheart functionheart preservationimprovedinsightlipid metabolismloss of functionmRNA Expressionmetabolomicsmortalitymyocardial damagenovelorgan injuryperipheral bloodpreclinical studyreconstitutionsepticskillstranscription factortreatment strategyuptake
项目摘要
Project Summary/Abstract
Sepsis is a severe condition that often results in life-threatening multiorgan dysfunction. This proposal
describes a 5-year research and training program that will permit Dr. Stephen Standage to develop as an
independent investigator conducting clinically relevant, basic and translational research in sepsis
pathogenesis. Having completed fellowship training in pediatric critical care medicine and building on a
background of basic research training in sepsis immunology, the applicant seeks to develop new knowledge
and skills to investigate how regulation of metabolic pathways influences organ dysfunction in sepsis with an
objective to identify key mechanisms and therapeutic interventions that may improve patient outcomes.
This research project specifically focuses on elucidating how PPARα influences cardiac energy production and
heart function in sepsis. PPARα is a nuclear hormone receptor transcription factor that regulates many
inflammatory and metabolic processes. Previous research has demonstrated that children with septic shock
have significant downregulation of PPARα in peripheral blood leukocytes. The applicant's preliminary studies
demonstrated that mice lacking PPARα (Ppara-/-) have much higher mortality in experimental sepsis, but
reconstitution with bone marrow from wild type mice did not rescue the mortality phenotype, indicating a critical
role for tissue PPARα in regulating organ injury and mortality in sepsis. Septic Ppara-/- mice have elevated
plasma and tissue markers of severe cardiac injury and show decreased heart function compared to wild type
mice, findings that are associated with lower fatty acid oxidation in the Ppara-/- group. Collectively, these data
support the overall hypothesis that PPARα preserves cardiac function in sepsis by activating fatty acid
oxidation and that augmenting cardiac PPARα signaling will improve survival. The specific aims of the
proposed investigations are to: 1) Define the role of PPARα expression in heart function and survival in sepsis
using a novel transgenic, cardiac-specific PPARα knock-out mouse and a mouse strain that over-expresses
PPARα in the heart; 2) Identify the metabolic pathways that influence PPARα dependent cardiac function in the
heart by measuring cardiac ATP production and substrate utilization, tissue gene expression and metabolite
levels, and by evaluating mitochondrial structure and function; and 3) Determine whether pharmacologic
PPARα activation ameliorates septic cardiac dysfunction and improves survival.
This work is significant and has high translational potential because PPARα signaling is a targetable
mechanism with FDA approved agonists already on the market. The hypotheses evaluated here challenge the
prevailing paradigm that sepsis morbidity and mortality result from immune dysregulation and findings will have
the potential to reframe the approach to treating this significant public health problem.
项目概要/摘要
脓毒症是一种严重的疾病,通常会导致危及生命的多器官功能障碍。这个提议
描述了一项为期 5 年的研究和培训计划,该计划将使 Stephen Standage 博士能够发展成为一名
独立研究者进行脓毒症的临床相关、基础和转化研究
发病。完成了儿科重症监护医学进修培训并建立了
脓毒症免疫学基础研究培训背景,申请人寻求发展新知识
以及研究代谢途径的调节如何影响脓毒症器官功能障碍的技能
目标是确定可以改善患者预后的关键机制和治疗干预措施。
该研究项目特别侧重于阐明 PPARα 如何影响心脏能量产生和
败血症时的心脏功能。 PPARα 是一种核激素受体转录因子,可调节许多
炎症和代谢过程。先前的研究表明,患有感染性休克的儿童
外周血白细胞中 PPARα 显着下调。申请人的初步研究
证明缺乏 PPARα (Ppara-/-) 的小鼠在实验性脓毒症中的死亡率要高得多,但是
用野生型小鼠的骨髓重建并不能挽救死亡表型,表明关键
组织 PPARα 在调节脓毒症器官损伤和死亡率中的作用。脓毒症 Ppara-/- 小鼠的
与野生型相比,严重心脏损伤的血浆和组织标志物显示心脏功能下降
小鼠中,发现与 Ppara-/- 组中的较低脂肪酸氧化有关。总的来说,这些数据
支持以下总体假设:PPARα 通过激活脂肪酸来保护脓毒症患者的心脏功能
氧化作用和增强心脏 PPARα 信号传导将提高生存率。该计划的具体目标
拟议的研究目的是: 1) 确定 PPARα 表达在脓毒症患者心脏功能和生存中的作用
使用新型转基因、心脏特异性 PPARα 敲除小鼠和过度表达的小鼠品系
PPARα 位于心脏; 2) 确定影响 PPARα 依赖性心脏功能的代谢途径
通过测量心脏 ATP 产生和底物利用率、组织基因表达和代谢物来检测心脏
水平,并通过评估线粒体结构和功能; 3) 确定是否具有药理作用
PPARα 激活可改善脓毒症性心脏功能障碍并提高生存率。
这项工作意义重大,并且具有很高的转化潜力,因为 PPARα 信号传导是一种可靶向的
机制与 FDA 批准的激动剂已经上市。这里评估的假设挑战了
普遍认为脓毒症发病率和死亡率是由免疫失调引起的,研究结果将有
重新制定治疗这一重大公共卫生问题的方法的潜力。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
NMR-based serum and urine metabolomic profile reveals suppression of mitochondrial pathways in experimental sepsis-associated acute kidney injury.
基于 NMR 的血清和尿液代谢组学谱揭示了实验性脓毒症相关急性肾损伤中线粒体途径的抑制。
- DOI:10.1152/ajprenal.00582.2020
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Standage,StephenW;Xu,Shenyuan;Brown,Lauren;Ma,Qing;Koterba,Adeleine;Lahni,Patrick;Devarajan,Prasad;Kennedy,MichaelA
- 通讯作者:Kennedy,MichaelA
Candidate Biomarkers for Sepsis-Associated Acute Kidney Injury Mechanistic Studies.
- DOI:10.1097/shk.0000000000001916
- 发表时间:2022-05-01
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Choline Supplementation Attenuates Experimental Sepsis-Associated Acute Kidney Injury.
- DOI:10.1152/ajprenal.00033.2022
- 发表时间:2022-07
- 期刊:
- 影响因子:0
- 作者:Denise C. Hasson;Miki Watanabe-Chailland;L. Romick-Rosendale;Adeleine Koterba;Dashiell S Miner;P. Lahni;Q. Ma;S. Goldstein;P. Devarajan;Stephen W. Standage
- 通讯作者:Denise C. Hasson;Miki Watanabe-Chailland;L. Romick-Rosendale;Adeleine Koterba;Dashiell S Miner;P. Lahni;Q. Ma;S. Goldstein;P. Devarajan;Stephen W. Standage
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephen Wade Standage其他文献
Stephen Wade Standage的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephen Wade Standage', 18)}}的其他基金
The Role of PPARa in Cardiac Dysfunction in Sepsis
PPARa 在脓毒症心脏功能障碍中的作用
- 批准号:
9576973 - 财政年份:2017
- 资助金额:
$ 16.2万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 16.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




